Incidence of hemolysis in patients with cardiogenic shock treated with impella percutaneous left ventricular assist device

Amit P. Badiye, Gabriel A. Hernandez, Italo Novoa, Sandra Chaparro

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Impella assist devices have been increasingly used in cardiogenic shock (CS). This study aims to assess the incidence of hemolysis when Impella support is used longer than 6 hours in CS. We retrospectively studied all patients who required Impella between April 2009 and September 2013. Demographic data and hemolysis indicators were sampled and analyzed using paired t-test. A total of 118 devices were placed and 40 used longer than 6 hours. The average time of support was 86.63 hours, and the 30 and 90 days of survival were 65% and 60%, respectively. After 24 hours of support, the hemoglobin (Hb) decreased significantly despite 17% of patients receiving blood transfusion (p = 0.0001). By the time of removal, 65% of patients were transfused to maintain a Hb of 10 mg/dl (p = 0.0014). The lactate dehydrogenase (LDH) increased to 5,201 U/L (n = 22; p = 0.0096), the bilirubin to 5.6 mg/dl (p = 0.008), and the haptoglobin level was 15.4 mg/dl (n = 25). The cumulative incidence of hemolysis was 62.5%. Hemolysis is a common occurrence in patients with long-term Impella support for CS, evaluated by the persistent decline in Hb and haptoglobin as well as increase in LDH and bilirubin. Strict monitoring of hemolysis parameters at baseline and at frequent intervals is crucial.

Original languageEnglish (US)
Pages (from-to)11-14
Number of pages4
JournalASAIO Journal
Volume62
Issue number1
DOIs
StatePublished - 2016

Fingerprint

Left ventricular assist devices
Heart-Assist Devices
Cardiogenic Shock
Hemoglobin
Hemolysis
Hemoglobins
Haptoglobins
L-Lactate Dehydrogenase
Bilirubin
Incidence
Blood
Equipment and Supplies
Monitoring
Blood Transfusion
Demography
Survival
Oxidoreductases

Keywords

  • Heart Failure
  • Heart-Assist Device
  • Hemoglobin
  • Shock

ASJC Scopus subject areas

  • Biophysics
  • Biomaterials
  • Bioengineering
  • Biomedical Engineering
  • Medicine(all)

Cite this

Incidence of hemolysis in patients with cardiogenic shock treated with impella percutaneous left ventricular assist device. / Badiye, Amit P.; Hernandez, Gabriel A.; Novoa, Italo; Chaparro, Sandra.

In: ASAIO Journal, Vol. 62, No. 1, 2016, p. 11-14.

Research output: Contribution to journalArticle

@article{827bb52048154321a2685fb2c4806867,
title = "Incidence of hemolysis in patients with cardiogenic shock treated with impella percutaneous left ventricular assist device",
abstract = "Impella assist devices have been increasingly used in cardiogenic shock (CS). This study aims to assess the incidence of hemolysis when Impella support is used longer than 6 hours in CS. We retrospectively studied all patients who required Impella between April 2009 and September 2013. Demographic data and hemolysis indicators were sampled and analyzed using paired t-test. A total of 118 devices were placed and 40 used longer than 6 hours. The average time of support was 86.63 hours, and the 30 and 90 days of survival were 65{\%} and 60{\%}, respectively. After 24 hours of support, the hemoglobin (Hb) decreased significantly despite 17{\%} of patients receiving blood transfusion (p = 0.0001). By the time of removal, 65{\%} of patients were transfused to maintain a Hb of 10 mg/dl (p = 0.0014). The lactate dehydrogenase (LDH) increased to 5,201 U/L (n = 22; p = 0.0096), the bilirubin to 5.6 mg/dl (p = 0.008), and the haptoglobin level was 15.4 mg/dl (n = 25). The cumulative incidence of hemolysis was 62.5{\%}. Hemolysis is a common occurrence in patients with long-term Impella support for CS, evaluated by the persistent decline in Hb and haptoglobin as well as increase in LDH and bilirubin. Strict monitoring of hemolysis parameters at baseline and at frequent intervals is crucial.",
keywords = "Heart Failure, Heart-Assist Device, Hemoglobin, Shock",
author = "Badiye, {Amit P.} and Hernandez, {Gabriel A.} and Italo Novoa and Sandra Chaparro",
year = "2016",
doi = "10.1097/MAT.0000000000000290",
language = "English (US)",
volume = "62",
pages = "11--14",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Incidence of hemolysis in patients with cardiogenic shock treated with impella percutaneous left ventricular assist device

AU - Badiye, Amit P.

AU - Hernandez, Gabriel A.

AU - Novoa, Italo

AU - Chaparro, Sandra

PY - 2016

Y1 - 2016

N2 - Impella assist devices have been increasingly used in cardiogenic shock (CS). This study aims to assess the incidence of hemolysis when Impella support is used longer than 6 hours in CS. We retrospectively studied all patients who required Impella between April 2009 and September 2013. Demographic data and hemolysis indicators were sampled and analyzed using paired t-test. A total of 118 devices were placed and 40 used longer than 6 hours. The average time of support was 86.63 hours, and the 30 and 90 days of survival were 65% and 60%, respectively. After 24 hours of support, the hemoglobin (Hb) decreased significantly despite 17% of patients receiving blood transfusion (p = 0.0001). By the time of removal, 65% of patients were transfused to maintain a Hb of 10 mg/dl (p = 0.0014). The lactate dehydrogenase (LDH) increased to 5,201 U/L (n = 22; p = 0.0096), the bilirubin to 5.6 mg/dl (p = 0.008), and the haptoglobin level was 15.4 mg/dl (n = 25). The cumulative incidence of hemolysis was 62.5%. Hemolysis is a common occurrence in patients with long-term Impella support for CS, evaluated by the persistent decline in Hb and haptoglobin as well as increase in LDH and bilirubin. Strict monitoring of hemolysis parameters at baseline and at frequent intervals is crucial.

AB - Impella assist devices have been increasingly used in cardiogenic shock (CS). This study aims to assess the incidence of hemolysis when Impella support is used longer than 6 hours in CS. We retrospectively studied all patients who required Impella between April 2009 and September 2013. Demographic data and hemolysis indicators were sampled and analyzed using paired t-test. A total of 118 devices were placed and 40 used longer than 6 hours. The average time of support was 86.63 hours, and the 30 and 90 days of survival were 65% and 60%, respectively. After 24 hours of support, the hemoglobin (Hb) decreased significantly despite 17% of patients receiving blood transfusion (p = 0.0001). By the time of removal, 65% of patients were transfused to maintain a Hb of 10 mg/dl (p = 0.0014). The lactate dehydrogenase (LDH) increased to 5,201 U/L (n = 22; p = 0.0096), the bilirubin to 5.6 mg/dl (p = 0.008), and the haptoglobin level was 15.4 mg/dl (n = 25). The cumulative incidence of hemolysis was 62.5%. Hemolysis is a common occurrence in patients with long-term Impella support for CS, evaluated by the persistent decline in Hb and haptoglobin as well as increase in LDH and bilirubin. Strict monitoring of hemolysis parameters at baseline and at frequent intervals is crucial.

KW - Heart Failure

KW - Heart-Assist Device

KW - Hemoglobin

KW - Shock

UR - http://www.scopus.com/inward/record.url?scp=84952716366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952716366&partnerID=8YFLogxK

U2 - 10.1097/MAT.0000000000000290

DO - 10.1097/MAT.0000000000000290

M3 - Article

C2 - 26418208

AN - SCOPUS:84952716366

VL - 62

SP - 11

EP - 14

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 1

ER -